Clinical Trial Details

A Phase 1 Study in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Complete Title: A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF CUE-101 MONOTHERAPY IN PATIENTS WITH HPV+ RECURRENT/ METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Trial Phase: I
Investigator: Cristina Rodriguez

This is a multi center, open-label, phase 1 dose escalation and expansion study evaluating the safety, anti-tumor effect, and immunogenicity of CUE-101 in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

Keywords:
  • Head and Neck Cancer
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Checklist icon

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.

Adult
I
Cristina Rodriguez
RG1005866
NCT03978689
A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF CUE-101 MONOTHERAPY IN PATIENTS WITH HPV+ RECURRENT/ METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Head and Neck Cancer